Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
17 Outubro 2023 - 8:00AM
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage
biotechnology company developing novel molecular glue degrader
(MGD)-based medicines, today announced it has entered into a
strategic collaboration and licensing agreement with global
healthcare leader Roche to discover and develop MGDs against
targets in cancer and neurological diseases previously considered
impossible to drug.
“We are excited to partner with Roche, a leading healthcare and
one of the world’s top oncology companies. Our QuEEN™ discovery
engine, a highly validated and industry-leading molecular glue
degrader platform, has been the cornerstone for Monte Rosa’s
success, driving the discovery and development of our exquisitely
selective MGDs successfully into the clinic. This collaboration
will enable and accelerate expansion of our platform into
neuroscience and additional areas of oncology. We believe our
decision to partner with Roche, a company that shares our vision
and drive, will amplify our collective strengths and capabilities
to accelerate the development of transformative treatments for
patients across several indications,” said Markus Warmuth, M.D.,
CEO of Monte Rosa Therapeutics.
James Sabry, M.D., Ph.D., Global Head of Pharma Partnering at
Roche, added: "We believe that molecular glue degraders are a
powerful new class of small molecules that target disease-related
proteins that traditional approaches have been unable to address.
Together with Monte Rosa, we look forward to tackling high-value
targets in both oncology and neuroscience with the goal of
unlocking new therapeutic possibilities."
Under the terms of the agreement, Monte Rosa Therapeutics will
receive an upfront payment of $50 million, and is eligible to
receive future preclinical, clinical, commercial and sales
milestone payments that could exceed $2 billion, as well as tiered
royalties. The parties also agreed on a mechanism to expand the
collaboration on multiple targets within the first two years. In
that case, additional payments for nomination, preclinical,
clinical, commercial and sales milestones are due, as well as
tiered royalties on the resulting products. Monte Rosa Therapeutics
will lead discovery and preclinical activities against multiple
select cancer and neurological disease targets to a defined point.
Roche gains the right to exclusively pursue further preclinical and
clinical development of the compounds. Monte Rosa retains full
ownership of its pipeline programs.
About Monte RosaMonte Rosa Therapeutics is a
clinical-stage biotechnology company developing highly selective
molecular glue degrader (MGD) medicines for patients living with
serious diseases in the areas of oncology, autoimmune and
inflammatory diseases, and more. MGDs are small molecule protein
degraders that have the potential to treat many diseases that other
modalities, including other degraders, cannot. Monta Rosa’s QuEEN™
(Quantitative and Engineered Elimination of Neosubstrates)
discovery engine combines AI-guided chemistry, diverse chemical
libraries, structural biology and proteomics to identify degradable
protein targets and rationally design MGDs with unprecedented
selectivity. The QuEEN discovery engine enables access to a
wide-ranging and differentiated target space of well-validated
biology across multiple therapeutic areas. Monte Rosa has developed
the industry’s leading pipeline of MGDs, which spans oncology,
autoimmune and inflammatory disease and beyond. For more
information, visit www.monterosatx.com
Forward-Looking StatementsThis communication
includes express and implied “forward-looking statements,”
including forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include all statements that are not historical facts and
in some cases, can be identified by terms such as “may,” “might,”
“will,” “could,” “would,” “should,” “expect,” “intend,” “plan,”
“objective,” “anticipate,” “believe,” “estimate,” “predict,”
“potential,” “continue,” “ongoing,” or the negative of these terms,
or other comparable terminology intended to identify statements
about the future. Forward-looking statements contained herein
include, but are not limited to, statements about our QuEEN™
discovery engine and our view of its potential for the ongoing
discovery and development of MGDs, including highly selective MGDs,
our beliefs regarding the potential of MGDs to target previously
unaddressable disease-related proteins, our expectations for our
collaboration with Roche, including the discovery and development
of MGDs therefrom, the acceleration of the expansion of our
platform and the development of treatments across several
indications, our expectations and estimates of potential future
payments available under the collaboration, the advancement of our
preclinical programs, pipeline and the various products therein,
statements around the advancement and application of our pipeline
and platform, including our lead program, MRT-2359, and statements
concerning our expectations regarding our ability to nominate and
the timing of our nominations of additional targets, product
candidates, and development candidates, as well as our expectations
of success for our programs, among others. By their nature, these
statements are subject to numerous risks and uncertainties,
including those risks and uncertainties set forth in our most
recent Annual Report on Form 10-K for the year ended December 31,
2022, filed with the U.S. Securities and Exchange Commission on
March 16, 2023, and any subsequent filings, that could cause actual
results, performance or achievement to differ materially and
adversely from those anticipated or implied in the statements. You
should not rely upon forward-looking statements as predictions of
future events. Although our management believes that the
expectations reflected in our statements are reasonable, we cannot
guarantee that the future results, performance, or events and
circumstances described in the forward-looking statements will be
achieved or occur. Recipients are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date such statements are made and should not be construed as
statements of fact. We undertake no obligation to publicly update
any forward-looking statements, whether as a result of new
information, any future presentations, or otherwise, except as
required by applicable law. Certain information contained in these
materials and any statements made orally during any presentation of
these materials that relate to the materials or are based on
studies, publications, surveys and other data obtained from
third-party sources and our own internal estimates and research.
While we believe these third-party studies, publications, surveys
and other data to be reliable as of the date of these materials, we
have not independently verified, and make no representations as to
the adequacy, fairness, accuracy or completeness of, any
information obtained from third-party sources. In addition, no
independent source has evaluated the reasonableness or accuracy of
our internal estimates or research and no reliance should be made
on any information or statements made in these materials relating
to or based on such internal estimates and research.
InvestorsAndrew Funderburk, Kendall
IRir@monterosatx.com
MediaCory Tromblee, Scient
PRmedia@monterosatx.com
Monte Rosa Therapeutics (NASDAQ:GLUE)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Monte Rosa Therapeutics (NASDAQ:GLUE)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024